孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘临床效果分析

Analysis of the Clinical Effect of Montelukast Sodium Combined with Salmeterol and Fluticasone Propionate Powder Inhalation in the Treatment of Bronchial Asthma

目的:探究孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘临床效果。方法:将从2016年6月-2017年12月在笔者所在医院就诊的112例支气管哮喘患者,按照数字随机表法随机分为对照组和试验组,每组56例。两组患者均实施鼻导管吸氧治疗、保持水电解质平衡、抗感染治疗、纠正酸碱失衡、补液治疗等常规对症治疗。对照组患者使用沙美特罗替卡松粉吸入剂治疗,试验组患者在对照组基础上,联合应用孟鲁司特钠进行治疗。探究两组患者治疗后的有效率和炎性因子表达水平。结果:(1)试验组患者总有效率为96.43%,显著高于对照组的69.64%(字2=5.986,P<0.05)。(2)在治疗后,试验组患者肿瘤坏死因子水平(453.7±78.3)ng/L,显著低于对照组患者的(816.7±98.7)ng/L(t=4.987,P<0.05);试验组患者治疗后白介素-6水平(0.17±0.04)ng/L,显著低于对照组患者的(0.30±0.05)ng/L(t=6.253,P<0.05)。(3)试验组患者在治疗后MMEF、FEV1、PEF指标水平分别为(0.79±0.28)L/s、(1.54±0.16)L、(4.85±1.21)L/s,均显著优于对照组患者(P<0.05)。结论:孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘,可以显著提高临床治疗效果,改善患者炎症因子水平,改善患者的肺功能,在临床中具有推广和应用价值。

Objective：To investigate the clinical effect of Montelukast Sodium combined with Salmeterol and Fluticasone Propionate Powder Inhalation in the treatment of bronchial asthma.Method：A total of 112 patients with bronchial asthma diagnosed in our hospital from June 2016 to December 2017 were randomly divided into the control group and the experimental group according to digital random table method,56 patients in each group.Both groups were implemented nasal catheter oxygen therapy,maintaining water and electrolyte balance,anti-infective treatment,acid-base imbalance correction,rehydration therapy and other conventional symptomatic treatment.Patients in the control group were treated with Salmeterol and Fluticasone Propionate Powder Inhalation,patients in the experimental group were treated with Montelukast Sodium on the basis of the control group.The efficacy and inflammatory factor expression levels after treatment were investigated in both groups of patients.Result：（1）The total effective rate in the experimental group was 96.43%,which was significantly higher than 69.64% in the control group（ X2=5.986,P〈0.05）.（2）After treatment,the tumor necrosis factor in the experimental group was（453.7±78.3）ng/L,which was significantly lower than（816.7±98.7）ng/L in the control group（t=4.987,P〈0.05）,after treatment,interleukin-6 in the experimental group was（0.17±0.04）ng/L,which was significantly lower than（0.30±0.05）ng/L in the control group（t=6.253,P〈0.05）.（3）The levels of MMEF,FEV1,and PEF in the experimental group were（0.79±0.28）L/s,（1.54±0.16）L,and（4.85±1.21）L/s,respectively,which were significantly better than those of the control group（P〈0.05）.Conclusion：The treatment of bronchial asthma with Montelukast Sodium combined with Salmeterol and Fluticasone Propionate Powder Inhalation is more effective in improving bronchial asthma,improving the level of inflammatory factors in patients and the lung function of patients.It has the value of promotion and application in clinical practice.